Who Owns IN8bio Stock?
NASDAQ: INABHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 9, 3:42 PM ET
Ownership breakdown
- Held by institutions
- 38.45%
- Held by insiders
- 7.58%
- Institutional holders
- 22
- Institutions 38.4%
- Insiders 7.6%
- Public and other 54.0%
Who owns IN8bio stock?
Institutional investors own about 38.4% of IN8bio's shares, spread across 22 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 7.58% of INAB.
The largest institutional holders are Alyeska Investment Group, L.p. (9.58%), Franklin Resources, Inc. (9.28%) and 683 Capital Management LLC (7.35%). Together, the top 10 institutions control 37.4% of shares outstanding. In their latest filings, 3 of the top 10 institutions increased their INAB positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of INAB
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Alyeska Investment Group, L.p. | 944.32K | 9.58% | 0.0% |
| Franklin Resources, Inc. | 914.53K | 9.28% | 0.0% |
| 683 Capital Management LLC | 724.64K | 7.35% | 0.0% |
| Stonepine Capital Management, LLC | 695.29K | 7.05% | +4.8% |
| Vanguard Capital Management LLC | 88.86K | 0.90% | 0.0% |
| Bios Capital Management, LP | 80.96K | 0.82% | -51.8% |
| Geode Capital Management, LLC | 72.55K | 0.74% | -15.9% |
| Citadel Advisors Llc | 63.05K | 0.64% | +100.0% |
| Oppenheimer & Co Inc | 63.04K | 0.64% | +162.3% |
| Vanguard Fiduciary Trust Co | 43.57K | 0.44% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of INAB
| Fund | Shares | % Held |
|---|---|---|
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 332.08K | 3.37% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 88.86K | 0.90% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 46.40K | 0.47% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 12.23K | 0.12% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 2.04K | 0.02% |
| Blackstone Alternative Investment Fd.s-Blackstone Alternative Multi-St | 200 | 0.00% |
Frequently asked questions
Who is the largest shareholder of IN8bio?
Alyeska Investment Group, L.p. is the largest institutional shareholder of INAB, owning 9.58% of shares outstanding (944.32K shares) as of its latest 13F filing.
What percentage of IN8bio is owned by institutions?
Institutions own about 38.4% of INAB shares and 41.6% of the public float.
How much of IN8bio do insiders own?
Insiders, such as officers and directors, own about 7.58% of INAB shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.